From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Dacetuzumab dose, mg/kg
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Day 1
Day 4
Day 8
Day 15
Day 22
Day 29
Day 36
Cycle 1
1
2
4
8
Restage
Cycles 2-12
—